From L to R: Manifold Bio co-founders Gleb Kuznetsov (CEO), Shane Lofgren (head of BD) and Pierce Ogden (CSO)

Pro­tein ther­a­peu­tics biotech us­ing 'pro­tein bar­codes' in drug de­vel­op­ment se­cures new fi­nanc­ing — led by Jeff Hu­ber

Two years af­ter kick­ing things off with $5.4 mil­lion, a George Church spin­out is re­fill­ing its cof­fers to fu­el its ef­forts tack­ling pro­tein ther­a­peu­tics R&D.

Boston biotech Man­i­fold Bio an­nounced the new Se­ries A Thurs­day, led by new VC Tri­atom­ic Cap­i­tal, rais­ing $40 mil­lion to ad­vance its in­ter­nal pipeline and ex­pand its plat­form ca­pa­bil­i­ties. CEO and co-founder Gleb Kuznetsov tells End­points News that the fi­nanc­ing should last the biotech close to 2.5 years, de­pend­ing on how fast the com­pa­ny spends it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.